MCID: DPH001
MIFTS: 63

Diphtheria

Categories: Blood diseases, Infectious diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Diphtheria

MalaCards integrated aliases for Diphtheria:

Name: Diphtheria 12 77 54 60 56 44 3 15 17 74
Corynebacterium Infections 45 74
Corynebacterium Infection 12

Characteristics:

Orphanet epidemiological data:

60
diphtheria
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11405
MeSH 45 D003354
ICD10 34 A36 A36.9
MESH via Orphanet 46 D004165
ICD10 via Orphanet 35 A36.0 A36.1 A36.2 more
UMLS via Orphanet 75 C0012546
Orphanet 60 ORPHA1679

Summaries for Diphtheria

MedlinePlus : 44 Diphtheria is a serious bacterial infection. You can catch it from a person who has the infection and coughs or sneezes. You can also get infected by coming in contact with an object, such as a toy, that has bacteria on it. Diphtheria usually affects the nose and throat. Symptoms include Sore throat Swollen glands in the neck Fever Weakness Your doctor will diagnose it based on your signs and symptoms and a lab test. Getting treatment for diphtheria quickly is important. If your doctor suspects that you have it, you'll start treatment before the lab tests come back. Treatment is with antibiotics. The diphtheria, pertussis, and tetanus vaccine can prevent diphtheria, but its protection does not last forever. Children need another dose, or booster, at about age 12. Then, as adults, they should get a booster every 10 years. Diphtheria is very rare in the United States because of the vaccine. Centers for Disease Control and Prevention

MalaCards based summary : Diphtheria, also known as corynebacterium infections, is related to tetanus and leukemia, acute myeloid, and has symptoms including fever, pruritus and tinnitus. An important gene associated with Diphtheria is HBEGF (Heparin Binding EGF Like Growth Factor), and among its related pathways/superpathways are Developmental Biology and Cytokine Signaling in Immune system. The drugs Natalizumab and Iron have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and skin, and related phenotypes are Increased viability with SS1P at EC90 and growth/size/body region

Disease Ontology : 12 A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys.

CDC : 3 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Diphtheria causes a thick covering in the back of the throat. It can lead to difficulty breathing, heart failure, paralysis, and even death. CDC recommends vaccines for infants, children, teens and adults to prevent diphtheria.

Wikipedia : 77 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Signs and symptoms may... more...

Related Diseases for Diphtheria

Diseases related to Diphtheria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 266)
# Related Disease Score Top Affiliating Genes
1 tetanus 31.3 IL13 IL2 IL2RA
2 leukemia, acute myeloid 29.5 CSF2 IL2 IL3 IL3RA PARP1
3 burns 29.5 ALB CSF2
4 schistosomiasis 29.2 ALB IL13 IL2
5 keratoconjunctivitis 28.9 IL13 IL2 IL3
6 cutaneous diphtheria 12.7
7 pertussis 11.1
8 granulomatous lobular mastitis 11.1
9 pseudomembranous conjunctivitis 11.1
10 diphtheritic peritonitis 11.1
11 specific antibody deficiency 11.1
12 haemophilus influenzae 10.8
13 hepatitis 10.7
14 hepatitis b 10.7
15 poliomyelitis 10.6
16 measles 10.6
17 scarlet fever 10.5
18 leukemia 10.5
19 rubella 10.4
20 mumps 10.4
21 influenza 10.3
22 croup 10.3
23 pityriasis rubra pilaris 10.3
24 myeloid leukemia 10.2
25 smallpox 10.2
26 variola major 10.2
27 endocarditis 10.2
28 sudden infant death syndrome 10.2
29 myocarditis 10.2
30 atrial standstill 1 10.1
31 typhoid fever 10.1
32 arthritis 10.1
33 cholera 10.1
34 chickenpox 10.1
35 glioblastoma 10.1
36 lymphocytic leukemia 10.1
37 hepatitis a 10.1
38 pneumonia 10.1
39 bladder cancer 10.0
40 hemiplegia 10.0
41 melanoma 10.0
42 large granular lymphocyte leukemia 10.0 CSF2 IL2RA
43 cervicitis 10.0 IL2 IL2RA
44 visceral leishmaniasis 10.0 ALB EEF2 IL2
45 leukemia, acute lymphoblastic 10.0
46 erysipelas 10.0
47 neuritis 10.0
48 encephalopathy 10.0
49 atopic keratoconjunctivitis 10.0 IL2 IL3
50 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.0 CD9 IL2 IL2RA

Comorbidity relations with Diphtheria via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Diphtheria:



Diseases related to Diphtheria

Symptoms & Phenotypes for Diphtheria

UMLS symptoms related to Diphtheria:


fever, pruritus, tinnitus, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Diphtheria according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with SS1P at EC90 GR00376-A-1 8.92 DPH1 DPH2 DPH3 FURIN

MGI Mouse Phenotypes related to Diphtheria:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.1 CD9 CSF2 DPH1 DPH3 EEF2 FURIN
2 hematopoietic system MP:0005397 9.96 CD9 CSF2 DPH1 DPH2 FURIN IL13
3 embryo MP:0005380 9.91 CSF2 DPH1 DPH3 EEF2 FURIN PARP1
4 immune system MP:0005387 9.81 CD9 CSF2 DPH2 FURIN IL13 IL2
5 mortality/aging MP:0010768 9.77 ALB CSF2 DPH1 DPH2 DPH3 EEF2
6 respiratory system MP:0005388 9.17 CD9 CSF2 DPH1 HBEGF IL13 IL2

Drugs & Therapeutics for Diphtheria

Drugs for Diphtheria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4 189261-10-7
2
Iron Approved, Experimental Phase 4,Phase 3,Phase 2 7439-89-6, 15438-31-0 27284 23925
3
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
4
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
5
Etanercept Approved, Investigational Phase 4 185243-69-0
6
Adalimumab Approved Phase 4 331731-18-1 16219006
7
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
8
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
9 Daratumumab Approved Phase 4 945721-28-8
10
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
11
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Ixazomib Approved, Investigational Phase 4 1072833-77-2
14
Lenalidomide Approved Phase 4 191732-72-6 216326
15
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
16
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
17
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
18
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
19
Lopinavir Approved Phase 4 192725-17-0 92727
20
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2 7440-70-2 271
21
Lactitol Investigational Phase 4,Phase 3,Phase 2 585-88-6, 585-86-4 493591
22
BCG vaccine Investigational Phase 4,Phase 2,Not Applicable
23 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Bacterial Agents Phase 4,Phase 3,Not Applicable
31 Aluminum phosphate Phase 4,Phase 3,Phase 1,Phase 2
32 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
34 Antacids Phase 4,Phase 3,Phase 2,Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Diphtheria Antitoxin Phase 4,Phase 3
37 Antitoxins Phase 4,Phase 3
38 Tetanus Antitoxin Phase 4,Phase 3
39 Antidotes Phase 4,Phase 3,Phase 2
40 Keyhole-limpet hemocyanin Phase 4,Phase 1
41 Anticoagulants Phase 4,Phase 3,Phase 2
42 Calcium, Dietary Phase 4,Phase 3,Phase 2
43 Iron Chelating Agents Phase 4,Phase 3,Phase 2
44 Chelating Agents Phase 4,Phase 3,Phase 2
45 PENTA Phase 4,Phase 3,Phase 2,Not Applicable
46 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
47 Antirheumatic Agents Phase 4,Phase 2
48 Interleukin 1 Receptor Antagonist Protein Phase 4
49 MF59 oil emulsion Phase 4,Phase 2,Phase 3
50 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 595)
# Name Status NCT ID Phase Drugs
1 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
2 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
3 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
4 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
5 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
6 Pertussis (Tdap) Vaccination in Pregnancy Unknown status NCT01698346 Phase 4
7 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td Completed NCT00601835 Phase 4
8 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine Completed NCT03552445 Phase 4
9 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
10 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
11 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
12 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
13 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
14 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
15 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
16 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
17 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
18 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
19 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
20 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
21 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
22 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
23 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
24 Maternal Flu Vaccine Trial in Bamako, Mali Completed NCT01430689 Phase 4
25 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
26 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
27 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
28 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
29 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
30 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
31 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
32 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
33 Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Completed NCT02783170 Phase 4
34 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
35 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
36 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
37 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
38 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
39 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 Completed NCT00548171 Phase 4
40 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
41 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
42 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
43 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
44 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
45 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
46 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Completed NCT01362322 Phase 4
47 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
48 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
49 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
50 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4

Search NIH Clinical Center for Diphtheria

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: corynebacterium infections

Genetic Tests for Diphtheria

Anatomical Context for Diphtheria

MalaCards organs/tissues related to Diphtheria:

42
Testes, Heart, Skin, Kidney, T Cells, Tonsil, Lung

Publications for Diphtheria

Articles related to Diphtheria:

(show top 50) (show all 3221)
# Title Authors Year
1
Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'. ( 31062020 )
2019
2
Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. ( 30759132 )
2019
3
Detection and virulence potential of a phospholipase D-negative Corynebacterium ulcerans from a concurrent diphtheria and infectious mononucleosis case. ( 30771116 )
2019
4
Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study. ( 30785851 )
2019
5
Determinants of delayed or incomplete diphtheria-tetanus-pertussis vaccination in parallel urban and rural birth cohorts of 30,956 infants in Tanzania. ( 30808282 )
2019
6
Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review. ( 30814030 )
2019
7
Parasitic infections during pregnancy need not affect infant antibody responses to early vaccination against Streptococcus pneumoniae, diphtheria, or Haemophilus influenzae type B. ( 30818339 )
2019
8
Quantitative determination of bioactive proteins in diphtheria tetanus acellular pertussis (DTaP) vaccine by liquid chromatography tandem mass spectrometry. ( 30831450 )
2019
9
Real-time analysis of the diphtheria outbreak in forcibly displaced Myanmar nationals in Bangladesh. ( 30857521 )
2019
10
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. ( 30877773 )
2019
11
A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea. ( 30940999 )
2019
12
Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study. ( 30961907 )
2019
13
Tubercular Abscess near Diphtheria-Pertussis-Tetanus Injection Site: A Rare Complication of Immunization. ( 30983718 )
2019
14
Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. ( 31009031 )
2019
15
Proteomics of diphtheria toxoid vaccines reveals multiple proteins that are immunogenic and may contribute to protection of humans against Corynebacterium diphtheriae. ( 31036455 )
2019
16
Arsenic exposure and serum antibody concentrations to diphtheria and tetanus toxoid in children at age 5: A prospective birth cohort in Bangladesh. ( 31051324 )
2019
17
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2019
18
An unusual case of post-trauma polymicrobial cutaneous diphtheria. ( 30953325 )
2019
19
Imported Toxin-Producing Cutaneous Diphtheria - Minnesota, Washington, and New Mexico, 2015-2018. ( 30921303 )
2019
20
Whole genome sequencing suggests transmission of Corynebacterium diphtheriae-caused cutaneous diphtheria in two siblings, Germany, 2018. ( 30646974 )
2019
21
Cutaneous diphtheria in a returned traveller. ( 30288824 )
2019
22
Diphtheria in Children in Northern Haiti. ( 29688558 )
2019
23
Content and source analysis of popular tweets following a recent case of diphtheria in Spain. ( 30084926 )
2019
24
Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV). ( 30381690 )
2019
25
Cardiotoxicity Associated with Midazolam in a Patient with Diphtheria. ( 30394214 )
2019
26
Massive diphtheria outbreak among Rohingya refugees: lessons learnt. ( 30407562 )
2019
27
A comparison of three strategies for biopanning of phage-scFv library against diphtheria toxin. ( 30417355 )
2019
28
Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines. ( 30417710 )
2019
29
Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. ( 30444673 )
2019
30
Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regression. ( 30471957 )
2019
31
Use of different combination diphtheria-tetanus-acellular pertussis vaccines does not increase risk of 30-day infant mortality. A population-based linkage cohort study using administrative data from the Australian Childhood Immunisation Register and the National Death Index. ( 30503081 )
2019
32
Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies. ( 30621282 )
2019
33
A systematic review of adult tetanus-diphtheria-acellular (Tdap) coverage among healthcare workers. ( 30630694 )
2019
34
Clinico-epidemiological profile and predictors of outcome in children with diphtheria: a study from northern India. ( 30636517 )
2019
35
Neighbourhood influence on the fourth dose of diphtheria-tetanus-pertussis vaccination. ( 30639802 )
2019
36
Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children. ( 30668217 )
2019
37
Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D). ( 30670301 )
2019
38
A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults. ( 30686952 )
2019
39
Development and validation of magnetic bead pentaplex immunoassay for simultaneous quantification of murine serum IgG antibodies to acellular pertussis, diphtheria and tetanus antigens used in combination vaccines. ( 30690077 )
2019
40
NGS-based phylogeny of diphtheria-related pathogenicity factors in different Corynebacterium spp. implies species-specific virulence transmission. ( 30709334 )
2019
41
Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma. ( 30718426 )
2019
42
Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder. ( 30104424 )
2018
43
Summary of the NACI Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine. ( 31007617 )
2018
44
A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. ( 29217370 )
2018
45
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
46
Combined Poly(Lactide-Co-Glycolide) Microspheres Containing Diphtheria Toxoid for a Single-shot Immunization. ( 29238945 )
2018
47
Cardiac complications in diphtheria and predictors of outcomes. ( 29287886 )
2018
48
Treatment of MCPT8DTR mice with high- or low-dose diphtheria toxin leads to differential depletion of basophils and granulocyte-macrophage progenitors. ( 29315532 )
2018
49
Lichen planus following tetanus-diphtheria-acellular pertussis vaccination: A case report and review of the literature. ( 29326823 )
2018
50
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018

Variations for Diphtheria

Expression for Diphtheria

Search GEO for disease gene expression data for Diphtheria.

Pathways for Diphtheria

Pathways related to Diphtheria according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 CSF2 FURIN HBEGF IL2 IL2RA IL3
2
Show member pathways
13.25 CSF2 HBEGF IL13 IL2 IL2RA IL3
3
Show member pathways
13.19 ALB CD9 CSF2 IL2 IL2RA IL3
4
Show member pathways
13.12 CSF2 HBEGF IL13 IL2 IL2RA IL3
5
Show member pathways
12.94 EEF2 HBEGF IL2 IL2RA IL3 IL3RA
6 12.68 IL13 IL2 IL2RA IL3 IL3RA TXNRD1
7
Show member pathways
12.21 CSF2 IL13 IL2 IL2RA IL3 IL3RA
8
Show member pathways
12.14 HBEGF IL13 IL2 IL2RA IL3
9
Show member pathways
11.99 CSF2 IL2 IL2RA IL3 IL3RA
10
Show member pathways
11.96 IL13 IL2 IL2RA IL3 IL3RA
11
Show member pathways
11.9 IL13 IL2 IL2RA
12
Show member pathways
11.85 IL2 IL2RA IL3 IL3RA
13 11.78 CSF2 IL2 IL2RA IL3 IL3RA
14 11.76 IL2 IL2RA IL3 IL3RA
15 11.71 CSF2 IL13 IL2
16 11.69 IL13 IL2 IL2RA
17 11.65 CSF2 IL2 IL3RA
18 11.64 CD9 CSF2 IL2RA IL3 IL3RA
19 11.63 CSF2 IL13 IL2
20
Show member pathways
11.61 CSF2 IL2 IL2RA IL3
21 11.4 IL13 IL2 IL2RA
22
Show member pathways
11.25 CD9 EEF2 FURIN HBEGF TXNRD1
23
Show member pathways
11.13 DPH1 DPH2 DPH3 DPH7 EEF2 FURIN
24 11.12 IL13 IL2 IL2RA
25 11.11 CSF2 IL13 IL2 IL3
26 11.05 IL13 IL2
27 10.92 CSF2 IL13 IL2 IL3

GO Terms for Diphtheria

Cellular components related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ALB CSF2 EEF2 FURIN HBEGF IL13
2 external side of plasma membrane GO:0009897 9.46 CD9 IL13 IL2RA IL3RA
3 extracellular space GO:0005615 9.23 ALB CD9 CSF2 FURIN HBEGF IL13

Biological processes related to Diphtheria according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.83 CSF2 IL13 IL2 IL2RA IL3
2 regulation of signaling receptor activity GO:0010469 9.8 CSF2 HBEGF IL13 IL2 IL3
3 cell proliferation GO:0008283 9.7 DPH1 IL2RA TXNRD1
4 response to ethanol GO:0045471 9.67 EEF2 IL13 IL2
5 cytokine-mediated signaling pathway GO:0019221 9.63 CSF2 IL13 IL2 IL2RA IL3 IL3RA
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 CSF2 IL13 IL2 IL3
7 positive regulation of T cell differentiation GO:0045582 9.51 IL2 IL2RA
8 regulation of regulatory T cell differentiation GO:0045589 9.48 IL2 IL2RA
9 interleukin-2-mediated signaling pathway GO:0038110 9.46 IL2 IL2RA
10 MAPK cascade GO:0000165 9.43 CSF2 HBEGF IL2 IL2RA IL3 IL3RA
11 negative regulation of lymphocyte proliferation GO:0050672 9.37 IL2 IL2RA
12 regulation of T cell homeostatic proliferation GO:0046013 9.32 IL2 IL2RA
13 peptidyl-diphthamide biosynthetic process from peptidyl-histidine GO:0017183 8.92 DPH1 DPH2 DPH3 DPH7

Molecular functions related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CSF2 IL13 IL2 IL3
2 growth factor activity GO:0008083 8.92 CSF2 HBEGF IL2 IL3

Sources for Diphtheria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....